These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 6677890

  • 1. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M.
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract] [Full Text] [Related]

  • 2. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M, Kuźmińska A, Chotkowska E, Kurjata P, Polakowska M, Broda G, Rywik S.
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A, Bonaiuto M, Lanzafame F, Mileto A, Pernice F, Cinquegrani M, Mazza G, Micali G, Pangallo A, Fodale P.
    Clin Ter; 1988 Mar 15; 124(5):373-81. PubMed ID: 2974348
    [No Abstract] [Full Text] [Related]

  • 4. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Mar 15; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L, Németh Csóka M, Szám I, Pados G, Karádi I, Köszegi G, Kusztos R.
    Orv Hetil; 1986 Oct 05; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A, Sommariva D, Tirrito M, Bonfiglioli D, Pini C, Scandiani L, Orlandi S, Fasoli A.
    Clin Ter; 1987 Jul 15; 122(1):17-23. PubMed ID: 2973892
    [No Abstract] [Full Text] [Related]

  • 8. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W, Luley C, Scheffler W, Lehmann-Leo W, Schilling A, Wegscheider K.
    Med Welt; 1982 Apr 30; 33(17):631-7. PubMed ID: 7098826
    [No Abstract] [Full Text] [Related]

  • 9. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV].
    Chwistecki K, Mrukowicz M, Kopel E.
    Wiad Lek; 1985 Apr 01; 38(7):490-4. PubMed ID: 4013323
    [No Abstract] [Full Text] [Related]

  • 10. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
    Bradford RH, Goldberg AC, Schonfeld G, Knopp RH.
    Atherosclerosis; 1992 Jan 01; 92(1):31-40. PubMed ID: 1575820
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D, Scotti L, Baroni L, Beggi P, Fasoli A.
    Clin Ter; 1980 Mar 31; 92(6):649-55. PubMed ID: 7460493
    [No Abstract] [Full Text] [Related]

  • 13. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG, Patel ST, Falko JM, Newman HA, Hill DS.
    J Clin Endocrinol Metab; 1982 Jun 31; 54(6):1210-5. PubMed ID: 7076797
    [Abstract] [Full Text] [Related]

  • 14. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Jun 31; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E, Michajlik A, Wegrzyn B.
    Pol Tyg Lek; 1983 Sep 26; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II].
    Wirth A, Schlierf G, Middelhoff G, Arntz HR, Hansen W, Vollmar J, Bräuning C.
    Beitr Infusionther Klin Ernahr; 1983 Sep 26; 12():99-108. PubMed ID: 6316922
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K, Krempler F, Schellenberg B, Schlierf G.
    Acta Med Austriaca; 1979 Sep 26; 6(3):90-4. PubMed ID: 547652
    [Abstract] [Full Text] [Related]

  • 20. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P, Bittolo-Bon G, Alessandrini P.
    Clin Ter; 1981 Jul 15; 98(1):47-61. PubMed ID: 7249572
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.